Unaudited 2025 financial results: Total unaudited product and royalty revenue for full-year 2025 was approximately $823.4M. Total unaudited product revenue for full-year 2025 was approximately $587.8M. Sephience unaudited total net revenue for 2025 was approximately $112.1M. DMD franchise unaudited revenue for full-year 2025 was approximately $381.8M, including unaudited product revenue for Translarna of approximately $235.5M and for Emflaza of approximately $146.3M. PTC expects to report approximately $235.7M of full-year 2025 royalty revenue associated with Evr.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics price target raised to $90 from $78 at Morgan Stanley
- PTC Therapeutics Fully Monetizes Evrysdi Royalty Interest
- PTC Therapeutics announces Japanese MHLW approval of Sephience
- PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
- Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls